Christopher E. Goldring
Impact in
- Pharmacology top 0.05%
- Drug-Induced Hepatotoxicity and Protection
- Pharmacogenetics and Drug Metabolism
- Hepatology top 1%
- Liver physiology and pathology
Papers in
- Pharmacology 61
- Drug-Induced Hepatotoxicity and Protection 58
- Pharmacogenetics and Drug Metabolism 6
-
- Genomics, phytochemicals, and oxidative stress 27
- Pluripotent Stem Cells Research 15
- Co-authors
- B. Kevin Park (33 shared papers)Neil R. Kitteringham (44 shared papers)Ian M. Copple (23 shared papers)B. Kevin Park (29 shared papers)Rosalind E. Jenkins (19 shared papers)Rowena L. C. Sison-Young (16 shared papers)Daniel James Antoine (12 shared papers)Philip J. Starkey Lewis (11 shared papers)
- Journals
- Hepatology (11 papers)Archives of Toxicology (8 papers)Toxicological Sciences (8 papers)British Journal of Clinical Pharmacology (6 papers)Scientific Reports (5 papers)
- Partner nations
- United KingdomSwitzerlandUnited States
In The Last Decade
Christopher E. Goldring
154 papers receiving 10.2k citations
Christopher E. Goldring's Hit Papers
Peers
Comparison fields: 5 of 130
- Pharmacology 2.9k
- Hepatology 691
- Molecular Biology 3.3k
- Cancer Research 650
- Small Animals 309
Countries citing papers authored by Christopher E. Goldring
This map shows the geographic impact of Christopher E. Goldring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher E. Goldring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher E. Goldring more than expected).
Fields of papers citing papers by Christopher E. Goldring
This network shows the impact of papers produced by Christopher E. Goldring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher E. Goldring. The network helps show where Christopher E. Goldring may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher E. Goldring, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 158 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME Hit paper breakdown → | 2013 | 1055 |
| 2 | The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation Hit paper breakdown → | 2012 | 933 |
| 3 | Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease Hit paper breakdown → | 2016 | 594 |
| 4 | Circulating microRNAs as potential markers of human drug-induced liver injury Hit paper breakdown → | 2011 | 449 |
| 5 | Managing the challenge of chemically reactive metabolites in drug development Hit paper breakdown → | 2011 | 385 |
| 6 | Mechanistic Biomarkers Provide Early and Sensitive Detection of Acetaminophen-Induced Acute Liver Injury at First Presentation to Hospital Hit paper breakdown → | 2013 | 357 |
| 7 | 2007 | 300 | |
| 8 | 2014 | 289 | |
| 9 | Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study Hit paper breakdown → | 2018 | 269 |
| 10 | 2010 | 237 | |
| 11 | 2011 | 212 | |
| 12 | Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models Hit paper breakdown → | 2019 | 197 |
| 13 | 2011 | 193 | |
| 14 | 2014 | 190 | |
| 15 | 2004 | 178 | |
| 16 | 2012 | 177 | |
| 17 | 2015 | 158 | |
| 18 | 2010 | 152 | |
| 19 | 2003 | 136 | |
| 20 | 2008 | 115 |
About Christopher E. Goldring
Christopher E. Goldring is a scholar working on Pharmacology, Molecular Biology, Hepatology, Cancer Research and Oncology, having authored 158 papers that have together received 10.5k indexed citations. Recurring topics across this work include Drug-Induced Hepatotoxicity and Protection (58 papers), Genomics, phytochemicals, and oxidative stress (27 papers), Pluripotent Stem Cells Research (15 papers), Liver physiology and pathology (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers), Pharmacogenetics and Drug Metabolism (6 papers), Drug Transport and Resistance Mechanisms (6 papers) and Animal testing and alternatives (5 papers). The work is most often cited by research in Pharmacology (2.9k citations), Hepatology (691 citations), Molecular Biology (3.3k citations), Cancer Research (650 citations) and Small Animals (309 citations). Christopher E. Goldring has collaborated with scholars based in United Kingdom, Switzerland and United States. Frequent co-authors include B. Kevin Park, Neil R. Kitteringham, Ian M. Copple, B. Kevin Park, Rosalind E. Jenkins, Rowena L. C. Sison-Young, Daniel James Antoine, Philip J. Starkey Lewis, James W. Dear and Joanne Walsh. Their work appears in journals such as Hepatology, Archives of Toxicology, Toxicological Sciences, British Journal of Clinical Pharmacology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.